Evolent Health targets $1.95B revenue, $190M adj. EBITDA for 2023 at Investor Day

Evolent Health, Inc.

2023 revenue outlook midpoint $1.95B; adjusted EBITDA midpoint $190M.
Revenue CAGR of 39% from Q4 2019 to Q1 2023; Q1 2023 revenue $427.7M.
Cross-sell opportunity of $50B out of $150B specialty TAM; revenue renewal rate ~110% in 2022.
Performance Suite mature flow-through margins estimated at 12-18%; capital-light model emphasized.
TTM adjusted EBITDA $132.6M; TTM revenue (ex-divested) $1.35B.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.